免费获得国外相关药品,最快 1 个工作日回馈药物信息

出境医 / 临床实验 / Light Therapy on Major Depression Disorder

Light Therapy on Major Depression Disorder

Study Description
Brief Summary:

Background:

Major depression disorder is a common psychological disease. It is the second-ranked cause of disability worldwide. The pathophysiology is not yet understood. The main theory is monoaminergic theory based on the effect of monoaminergic drugs. Current treatment includes psychotherapy, medication and electroconvulsive therapy. The onset of action for antidepressant is often slow, therefore strategies to improve the outcome are important. Bright light therapy has been found to be effective in reducing the severity of depression not only in seasonal affective disorder but also in other affective disorder. Previous meta-analyses of light therapy for non-seasonal major depression, however, has yielded conflicting evidence for efficacy.

Purpose:

  1. To investigate possible imaging biomarkers of major depression disorder
  2. To evaluate the effect of light therapy on depression

Materials and Methods:

This prospective study will recruit 100 patients, randomized into 2 study groups: (1) antidepressant plus treatment light, and (2) antidepressant plus placebo light. All patients will accept a thorough psychological evaluation (including Hamilton Depression Rating Scale, Montgomery-Asberg Depression Rating Scale, Clinical Global Impression-Severity and Patient Health Questionnaire-9 items) at baseline and at the 1st, 2nd, 4th, 8th week during the 8-week experiment intervention, by a blind assessor. Mini-International Neuropsychiatric Interview (MINI) and Morningness- Eveningness Questionnaire-Self-Assessment Version (MEQ-SA) were only evaluated at baseline. Adverse events were evaluated at baseline, 2nd,4th,8th weeks. MRI study will be arranged at baseline and in 4-week experiment.

Predicted Results and Influence:

  1. To evaluate the additional effect of the treatment light on depression disorder
  2. To compare the difference of functional magnetic resonance imaging(fMRI), structural MRI among the two groups and between the patients with and without treatment effect in order to detect imaging biomarkers.

Condition or disease Intervention/treatment Phase
Depressive Disorder Device: Light therapy Not Applicable

Study Design
Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 100 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: Light Therapy on Major Depression Disorder
Actual Study Start Date : May 1, 2019
Estimated Primary Completion Date : December 2019
Estimated Study Completion Date : December 2019
Arms and Interventions
Arm Intervention/treatment
Active Comparator: Bright treatment light Device: Light therapy
Participants will be exposed to bright treatment light or red light 30 minutes every day for 4 weeks.

Placebo Comparator: Red light Device: Light therapy
Participants will be exposed to bright treatment light or red light 30 minutes every day for 4 weeks.

Outcome Measures
Primary Outcome Measures :
  1. Change from Baseline Hamilton Depression Rating Scale(HAM-D) at 1,2,4,8 weeks [ Time Frame: 1,2,4,8 weeks. ]

    Determine severity of depression (scores: 0-50)

    1. Depressed Mood (sadness, hopeless, helpless, worthless) (0-4 scores)
    2. Feelings of Guilt(0-4 scores)
    3. Suicide(0-4 scores)
    4. Insomnia - Early(0-2 scores)
    5. Insomnia - Middle(0-2 scores)
    6. Insomnia - Late(0-2 scores)
    7. Work and Activities(0-4 scores)
    8. Retardation (slowness of thought and speech; impaired ability to concentrate; decreased motor activity)(0-4 scores)
    9. Agitation(0-2 scores)
    10. Anxiety - Psychic(0-4 scores)
    11. Anxiety - Somatic(0-4 scores)
    12. Somatic Symptoms - Gastrointestinal(0-2 scores)
    13. Somatic Symptoms - General(0-2 scores)
    14. Genital Symptoms(0-2 scores)
    15. Hypochondriasis(0-4 scores)
    16. Loss of Weight(0-2 scores)
    17. Insight(0-2 scores)

    Scores below 7 generally represent the absence or remission of depression. Scores between 7-17 represent mild depression. Scores between 18-24 represent moderate depression. Scores 25 and above represent severe depression.


  2. Change from Baseline Montgomery-Asberg Depression Rating Scale(MADRS) at 1,2,4,8 weeks [ Time Frame: 1,2,4,8 weeks. ]

    Higher MADRS score indicates more severe depression, and each item yields a score of 0 to 6. The overall score ranges from 0 to 60.

    The questionnaire includes questions on the following symptoms

    1. Apparent sadness 2. Reported sadness 3. Inner tension 4. Reduced sleep 5. Reduced appetite 6. Concentration difficulties 7. Lassitude 8. Inability to feel 9. Pessimistic thoughts 10. Suicidal thoughts

    0 to 6 - normal /symptom absent 7 to 19 - mild depression 20 to 34 - moderate depression >34 - severe depression


  3. Change from Baseline Clinical Global Impression-Severity(CGI-S) at 1,2,4,8 weeks [ Time Frame: 1,2,4,8 weeks. ]

    The Clinical Global Impression - Severity scale (CGI-S) is a 7-point scale that requires the clinician to rate the severity of the patient's illness at the time of assessment, relative to the clinician's past experience with patients who have the same diagnosis. Possible ratings are:

    1. Normal, not at all ill
    2. Borderline mentally ill
    3. Mildly ill
    4. Moderately ill
    5. Markedly ill
    6. Severely ill
    7. Among the most extremely ill patients

  4. Change from Baseline Patient Health Questionnaire(PHQ-9) at 1,2,4,8 weeks [ Time Frame: 1,2,4,8 weeks. ]

    Depression screening by a nine-item in adults

    Over the last two weeks, how often have you been bothered by any of the following problems? (Scores: 0-27) 0:Not at all, 1:Several days, 2:More than half the days, 3:Nearly every day

    1. Little interest or pleasure in doing things
    2. Feeling down, depressed, or hopeless
    3. Trouble falling or staying asleep, or sleeping too much
    4. Feeling tired or having little energy
    5. Poor appetite or overeating
    6. Feeling bad about yourself, or that you are a failure, or have let yourself or your family down
    7. Trouble concentrating on things, such as reading the newspaper or watching television
    8. Moving or speaking so slowly that other people could have noticed? Or the opposite, being so fidgety or restless that you have been moving around a lot more than usual
    9. Thoughts that you would be better off dead or of hurting yourself in some way

    0-4:No depression, 5-9:Mild, 10-14:Moderate, 15-19:Moderately severe, 20-27: Severe



Secondary Outcome Measures :
  1. functional MRI [ Time Frame: 4 weeks ]

    Compare brain resting-state functional MRI change between these two arms.

    Including measures brain activity by detecting changes associated with blood flow and difference of Resting State Network which is a functionally connected neural network of apparent brain states.

    Increased strength of the activities or resting state network indicates neural activities are elevated within the regions of the brain or the network.

    Decreased strength of the activities or resting state network indicates neural activities are diminished within the regions of the brain or the network.


  2. Diffusion Tensor Imaging of MRI [ Time Frame: 4 weeks ]

    Compare brain Diffusion Tensor Imaging between these two arms.

    Evaluation the connection or fiber tracts between regions of the brain. Increased strength means enhanced connection between neuronal regions of the brain.

    Decreased strength means decreased connection between neuronal regions of the brain.



Eligibility Criteria
Layout table for eligibility information
Ages Eligible for Study:   20 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Fulfill diagnosis of Major depression disorder based on Diagnostic and Statistical Manual of Mental Disorders(DSM-V) for at least 6 weeks and under medication treatment for at least 4 weeks.
  2. at least 20 years old
  3. Hamilton Depression Rating Scale(HAMD-17) >= 13
  4. No medication change for at least 4 weeks and no medication change will be considered in the next 8 weeks.
  5. Agree to participate in this study and sign the permit.

Exclusion Criteria:

  1. Seasonal depression disorder
  2. Other psychological or neurological disorder
  3. Drug or alcohol abuse within 30 days
  4. Visual problem
  5. Light-induced seizure or migraine
  6. Contraindication for MRI study
  7. Severe illness and might be admitted in the near future
  8. Might have a long trip in the near future
Contacts and Locations

Contacts
Layout table for location contacts
Contact: Chun-Chao Huang 886-975835637 hcc.5306@mmh.org.tw

Locations
Layout table for location information
Taiwan
Mackay Memorial Hospital Recruiting
Taipei, Taiwan, 10449
Contact: Chun-Chao Huang, MD    886-975835637    hcc.5306@mmh.org.tw   
Sponsors and Collaborators
Mackay Memorial Hospital
National Tsing Hua University,Taiwan
Ministry of Science and Technology, Taiwan
Investigators
Layout table for investigator information
Principal Investigator: Chun-Chao Huang Mackay Memorial Hospital
Tracking Information
First Submitted Date  ICMJE March 27, 2019
First Posted Date  ICMJE May 7, 2019
Last Update Posted Date July 9, 2019
Actual Study Start Date  ICMJE May 1, 2019
Estimated Primary Completion Date December 2019   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: July 6, 2019)
  • Change from Baseline Hamilton Depression Rating Scale(HAM-D) at 1,2,4,8 weeks [ Time Frame: 1,2,4,8 weeks. ]
    Determine severity of depression (scores: 0-50)
    1. Depressed Mood (sadness, hopeless, helpless, worthless) (0-4 scores)
    2. Feelings of Guilt(0-4 scores)
    3. Suicide(0-4 scores)
    4. Insomnia - Early(0-2 scores)
    5. Insomnia - Middle(0-2 scores)
    6. Insomnia - Late(0-2 scores)
    7. Work and Activities(0-4 scores)
    8. Retardation (slowness of thought and speech; impaired ability to concentrate; decreased motor activity)(0-4 scores)
    9. Agitation(0-2 scores)
    10. Anxiety - Psychic(0-4 scores)
    11. Anxiety - Somatic(0-4 scores)
    12. Somatic Symptoms - Gastrointestinal(0-2 scores)
    13. Somatic Symptoms - General(0-2 scores)
    14. Genital Symptoms(0-2 scores)
    15. Hypochondriasis(0-4 scores)
    16. Loss of Weight(0-2 scores)
    17. Insight(0-2 scores)
    Scores below 7 generally represent the absence or remission of depression. Scores between 7-17 represent mild depression. Scores between 18-24 represent moderate depression. Scores 25 and above represent severe depression.
  • Change from Baseline Montgomery-Asberg Depression Rating Scale(MADRS) at 1,2,4,8 weeks [ Time Frame: 1,2,4,8 weeks. ]
    Higher MADRS score indicates more severe depression, and each item yields a score of 0 to 6. The overall score ranges from 0 to 60. The questionnaire includes questions on the following symptoms 1. Apparent sadness 2. Reported sadness 3. Inner tension 4. Reduced sleep 5. Reduced appetite 6. Concentration difficulties 7. Lassitude 8. Inability to feel 9. Pessimistic thoughts 10. Suicidal thoughts 0 to 6 - normal /symptom absent 7 to 19 - mild depression 20 to 34 - moderate depression >34 - severe depression
  • Change from Baseline Clinical Global Impression-Severity(CGI-S) at 1,2,4,8 weeks [ Time Frame: 1,2,4,8 weeks. ]
    The Clinical Global Impression - Severity scale (CGI-S) is a 7-point scale that requires the clinician to rate the severity of the patient's illness at the time of assessment, relative to the clinician's past experience with patients who have the same diagnosis. Possible ratings are:
    1. Normal, not at all ill
    2. Borderline mentally ill
    3. Mildly ill
    4. Moderately ill
    5. Markedly ill
    6. Severely ill
    7. Among the most extremely ill patients
  • Change from Baseline Patient Health Questionnaire(PHQ-9) at 1,2,4,8 weeks [ Time Frame: 1,2,4,8 weeks. ]
    Depression screening by a nine-item in adults Over the last two weeks, how often have you been bothered by any of the following problems? (Scores: 0-27) 0:Not at all, 1:Several days, 2:More than half the days, 3:Nearly every day
    1. Little interest or pleasure in doing things
    2. Feeling down, depressed, or hopeless
    3. Trouble falling or staying asleep, or sleeping too much
    4. Feeling tired or having little energy
    5. Poor appetite or overeating
    6. Feeling bad about yourself, or that you are a failure, or have let yourself or your family down
    7. Trouble concentrating on things, such as reading the newspaper or watching television
    8. Moving or speaking so slowly that other people could have noticed? Or the opposite, being so fidgety or restless that you have been moving around a lot more than usual
    9. Thoughts that you would be better off dead or of hurting yourself in some way
    0-4:No depression, 5-9:Mild, 10-14:Moderate, 15-19:Moderately severe, 20-27: Severe
Original Primary Outcome Measures  ICMJE
 (submitted: May 6, 2019)
  • Change from Baseline Hamilton Depression Rating Scale(HAM-D) at 2,4,8 weeks [ Time Frame: 2,4,8 weeks. ]
    Determine severity of depression (scores: 0-50)
    1. Depressed Mood (sadness, hopeless, helpless, worthless) (0-4 scores)
    2. Feelings of Guilt(0-4 scores)
    3. Suicide(0-4 scores)
    4. Insomnia - Early(0-2 scores)
    5. Insomnia - Middle(0-2 scores)
    6. Insomnia - Late(0-2 scores)
    7. Work and Activities(0-4 scores)
    8. Retardation (slowness of thought and speech; impaired ability to concentrate; decreased motor activity)(0-4 scores)
    9. Agitation(0-2 scores)
    10. Anxiety - Psychic(0-4 scores)
    11. Anxiety - Somatic(0-4 scores)
    12. Somatic Symptoms - Gastrointestinal(0-2 scores)
    13. Somatic Symptoms - General(0-2 scores)
    14. Genital Symptoms(0-2 scores)
    15. Hypochondriasis(0-4 scores)
    16. Loss of Weight(0-2 scores)
    17. Insight(0-2 scores)
    Scores below 7 generally represent the absence or remission of depression. Scores between 7-17 represent mild depression. Scores between 18-24 represent moderate depression. Scores 25 and above represent severe depression.
  • Change from Baseline Montgomery-Asberg Depression Rating Scale(MADRS) at 2,4,8 weeks [ Time Frame: 2,4,8 weeks. ]
    Higher MADRS score indicates more severe depression, and each item yields a score of 0 to 6. The overall score ranges from 0 to 60. The questionnaire includes questions on the following symptoms 1. Apparent sadness 2. Reported sadness 3. Inner tension 4. Reduced sleep 5. Reduced appetite 6. Concentration difficulties 7. Lassitude 8. Inability to feel 9. Pessimistic thoughts 10. Suicidal thoughts 0 to 6 - normal /symptom absent 7 to 19 - mild depression 20 to 34 - moderate depression >34 - severe depression
  • Change from Baseline Clinical Global Impression-Severity(CGI-S) at 2,4,8 weeks [ Time Frame: 2,4,8 weeks. ]
    The Clinical Global Impression - Severity scale (CGI-S) is a 7-point scale that requires the clinician to rate the severity of the patient's illness at the time of assessment, relative to the clinician's past experience with patients who have the same diagnosis. Possible ratings are:
    1. Normal, not at all ill
    2. Borderline mentally ill
    3. Mildly ill
    4. Moderately ill
    5. Markedly ill
    6. Severely ill
    7. Among the most extremely ill patients
  • Change from Baseline Patient Health Questionnaire(PHQ-9) at 2,4,8 weeks [ Time Frame: 2,4,8 weeks. ]
    Depression screening by a nine-item in adults Over the last two weeks, how often have you been bothered by any of the following problems? (Scores: 0-27) 0:Not at all, 1:Several days, 2:More than half the days, 3:Nearly every day
    1. Little interest or pleasure in doing things
    2. Feeling down, depressed, or hopeless
    3. Trouble falling or staying asleep, or sleeping too much
    4. Feeling tired or having little energy
    5. Poor appetite or overeating
    6. Feeling bad about yourself, or that you are a failure, or have let yourself or your family down
    7. Trouble concentrating on things, such as reading the newspaper or watching television
    8. Moving or speaking so slowly that other people could have noticed? Or the opposite, being so fidgety or restless that you have been moving around a lot more than usual
    9. Thoughts that you would be better off dead or of hurting yourself in some way
    0-4:No depression, 5-9:Mild, 10-14:Moderate, 15-19:Moderately severe, 20-27: Severe
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: May 6, 2019)
  • functional MRI [ Time Frame: 4 weeks ]
    Compare brain resting-state functional MRI change between these two arms. Including measures brain activity by detecting changes associated with blood flow and difference of Resting State Network which is a functionally connected neural network of apparent brain states. Increased strength of the activities or resting state network indicates neural activities are elevated within the regions of the brain or the network. Decreased strength of the activities or resting state network indicates neural activities are diminished within the regions of the brain or the network.
  • Diffusion Tensor Imaging of MRI [ Time Frame: 4 weeks ]
    Compare brain Diffusion Tensor Imaging between these two arms. Evaluation the connection or fiber tracts between regions of the brain. Increased strength means enhanced connection between neuronal regions of the brain. Decreased strength means decreased connection between neuronal regions of the brain.
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Light Therapy on Major Depression Disorder
Official Title  ICMJE Light Therapy on Major Depression Disorder
Brief Summary

Background:

Major depression disorder is a common psychological disease. It is the second-ranked cause of disability worldwide. The pathophysiology is not yet understood. The main theory is monoaminergic theory based on the effect of monoaminergic drugs. Current treatment includes psychotherapy, medication and electroconvulsive therapy. The onset of action for antidepressant is often slow, therefore strategies to improve the outcome are important. Bright light therapy has been found to be effective in reducing the severity of depression not only in seasonal affective disorder but also in other affective disorder. Previous meta-analyses of light therapy for non-seasonal major depression, however, has yielded conflicting evidence for efficacy.

Purpose:

  1. To investigate possible imaging biomarkers of major depression disorder
  2. To evaluate the effect of light therapy on depression

Materials and Methods:

This prospective study will recruit 100 patients, randomized into 2 study groups: (1) antidepressant plus treatment light, and (2) antidepressant plus placebo light. All patients will accept a thorough psychological evaluation (including Hamilton Depression Rating Scale, Montgomery-Asberg Depression Rating Scale, Clinical Global Impression-Severity and Patient Health Questionnaire-9 items) at baseline and at the 1st, 2nd, 4th, 8th week during the 8-week experiment intervention, by a blind assessor. Mini-International Neuropsychiatric Interview (MINI) and Morningness- Eveningness Questionnaire-Self-Assessment Version (MEQ-SA) were only evaluated at baseline. Adverse events were evaluated at baseline, 2nd,4th,8th weeks. MRI study will be arranged at baseline and in 4-week experiment.

Predicted Results and Influence:

  1. To evaluate the additional effect of the treatment light on depression disorder
  2. To compare the difference of functional magnetic resonance imaging(fMRI), structural MRI among the two groups and between the patients with and without treatment effect in order to detect imaging biomarkers.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Not Applicable
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Condition  ICMJE Depressive Disorder
Intervention  ICMJE Device: Light therapy
Participants will be exposed to bright treatment light or red light 30 minutes every day for 4 weeks.
Study Arms  ICMJE
  • Active Comparator: Bright treatment light
    Intervention: Device: Light therapy
  • Placebo Comparator: Red light
    Intervention: Device: Light therapy
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: May 6, 2019)
100
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE December 2019
Estimated Primary Completion Date December 2019   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Fulfill diagnosis of Major depression disorder based on Diagnostic and Statistical Manual of Mental Disorders(DSM-V) for at least 6 weeks and under medication treatment for at least 4 weeks.
  2. at least 20 years old
  3. Hamilton Depression Rating Scale(HAMD-17) >= 13
  4. No medication change for at least 4 weeks and no medication change will be considered in the next 8 weeks.
  5. Agree to participate in this study and sign the permit.

Exclusion Criteria:

  1. Seasonal depression disorder
  2. Other psychological or neurological disorder
  3. Drug or alcohol abuse within 30 days
  4. Visual problem
  5. Light-induced seizure or migraine
  6. Contraindication for MRI study
  7. Severe illness and might be admitted in the near future
  8. Might have a long trip in the near future
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 20 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Chun-Chao Huang 886-975835637 hcc.5306@mmh.org.tw
Listed Location Countries  ICMJE Taiwan
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03941301
Other Study ID Numbers  ICMJE 18MMHIS114e
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Responsible Party Mackay Memorial Hospital
Study Sponsor  ICMJE Mackay Memorial Hospital
Collaborators  ICMJE
  • National Tsing Hua University,Taiwan
  • Ministry of Science and Technology, Taiwan
Investigators  ICMJE
Principal Investigator: Chun-Chao Huang Mackay Memorial Hospital
PRS Account Mackay Memorial Hospital
Verification Date July 2019

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP